Summary
Eli Lilly and Company (LLY) has announced a change in its Chief Financial Officer (CFO) role. Anat Ashkenazi will be stepping down from her position as executive vice president and CFO to pursue opportunities outside the pharmaceutical industry. She will remain with the company until the end of July 2024 to ensure a smooth handover of her duties. Taking over as interim CFO, effective July 15, 2024, will be Gordon Brooks. Mr. Brooks brings extensive experience to the role, having been with Eli Lilly for 29 years and holding various senior finance positions. This includes his recent role as group vice president, controller, and corporate strategy, as well as prior leadership positions in financial planning, procurement, and internal audit. The company has stated there are no specific arrangements or understandings related to his selection, no family ties to current executives, and no related-party transactions.
Key Highlights
- 1Anat Ashkenazi resigns as Executive Vice President and Chief Financial Officer, effective July 15, 2024.
- 2Gordon Brooks appointed as interim Chief Financial Officer, starting July 15, 2024.
- 3Mr. Brooks possesses 29 years of experience within Eli Lilly's finance organization.
- 4Ms. Ashkenazi will stay with the company through the end of July 2024 to aid in the transition.
- 5Mr. Brooks has held numerous senior finance leadership roles, including group vice president, controller, and corporate strategy.
- 6No specific arrangements or understandings, family relationships, or Item 404(a) transactions are noted concerning Mr. Brooks' appointment.